Issuer-Sponsored by Tiziana Life Sciences*

TODAY’S TOP ALERT! 

Nasdaq: TLSA

📈 Join 1000’s of traders for LIVE TRADING action all day long in the

 Market Master’s Trading Room

Last night, I told you I told you that I had a word of caution about the market right now. ⚠️

I said, “I don’t think this is a great time to be a stock market buyer.”

That proved to be the right call when you look at the market carnage today.  I hope you avoided most of it like I have been telling my members the past couple of days.

I also told you that I would have a new trading idea for you this morning before the market opened that I thought had amazing potential.

I hope you paid attention to that as well because while the markets are bleeding red today, look at how that little stock has been doing as the day goes on…

👉  TLSA is TODAY’S #1 ALERT 👈

If you have not been watching Tiziana Life Sciences (TSLA) all day today – what are you doing??

Markets are in the toilet, and TLSA has put up over a 28% gain on the day so far (and we still have a few hours to go!)

Drop what you are doing and make sure this is on your radar before we head into the weekend.

As you can clearly see, this stock appears to be under accumulation and has been rising nearly all day long.

This is another big score for us so far!

The way things are going right now, I wouldn’t be surprised to see this keep gaining momentum.

The news this morning regarding their study with GLP-1 drugs could turn out to be a total gamechanger for the company.

It looks like the market really love this news, and you need to make sure you are watching all of the action today.

Things are looking amazing on my end.  I hope you are having a great end of the week as well!

In case you missed my email this morning (shame on you!) I insist that you go read it right now.

Also, I asked ChatGPT to put together some interesting notes together after researching TLSA.  Here is what AI has to say about the company right now…

1. A Game-Changing Solution for GLP-1 Side Effects

Tiziana’s nasal anti-CD3 therapy addresses a key issue in the $50+ billion GLP-1 drug market, dominated by drugs like Ozempic and Wegovy. These drugs are highly effective for obesity and diabetes but can cause muscle and bone loss over time. Tiziana’s therapy not only enhances GLP-1 benefits but sustains those effects after discontinuation, offering a unique edge in a competitive market.
Source: Tiziana Life Sciences Press Release (Jan. 10, 2025)

2. FDA Fast-Track and Expanding Clinical Trials

The FDA has granted Fast Track Designation to Tiziana’s lead candidate, Foralumab, for non-active secondary progressive multiple sclerosis (na-SPMS). The company is scaling its trials to include top institutions like Yale, Johns Hopkins, and Cornell. Fast Track Designation accelerates the approval process, putting Tiziana on a path to market its therapy faster.
Source: FDA Fast Track Designation Announcement

3. Multi-Disease Potential with a Unique Delivery Method

Foralumab is delivered intranasally, which simplifies treatment and reduces toxicity compared to traditional intravenous methods. This delivery mechanism allows the therapy to cross the blood-brain barrier, making it effective for conditions like MS, Alzheimer’s, and even Long Covid. The technology could transform treatment protocols across multiple fields.
Source: Tiziana’s Foralumab Overview

4. Backing by Heavyweights in Medical Research

Tiziana collaborates with prestigious researchers and institutions. Harvard’s Dr. Howard Weiner, a leading figure in immunotherapy, is a key investigator. Additionally, the company secured a $4 million NIH grant for Alzheimer’s research—strong validation of its science and potential.
Source: NIH Grant Announcement (2024)

5. Strategic Focus on Emerging Markets Like Obesity

With the Ozempic TikTok craze and growing focus on obesity treatments, Tiziana’s therapy is perfectly positioned. A recent study showed that its nasal anti-CD3 therapy works synergistically with GLP-1 drugs, tackling inflammation and improving metabolic health. This aligns Tiziana with one of the fastest-growing healthcare markets.
Source: Tiziana Study Results Press Release (Jan. 2025)
Market Data: Grand View Research on GLP-1 Market

So what are you waiting for?!

Put TLSA at the top of your watchlist right away!

To Your Success,

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Issuer Paid Content.  Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we were paid thirty five thousand dollars directly from Tiziana Life Sciences Ltd for a one day marketing program on January 10, 2025. Prior to this, we were paid thirty five thousand dollars directly from Tiziana Life Sciences Ltd for a two day marketing program on December 16-17, 2024 and also thirty five thousand dollars directly from Tiziana Life Sciences Ltd for a one day marketing program on December 4, 2024, and also thirty thousand dollars directly from Tiziana Life Sciences Ltd for a one-day marketing program on October 30, 2024. We also received seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on June 6, 2024. Before that, we were paid seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on April 22, 2024. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into  Tiziana Life Sciences Ltd might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.